Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated
Second clinical proof of concept achieved by DiversitAbplatform in past two months
Positive clinical results confirm that SABs fully-human polyclonal antibodies can be broadly neutralizing to both known and unknown viral variantsa valuable feature when addressing rapidly mutating pathogens
SAB plans to further evaluate SAB-176 in a Phase 2 influenza clinical trial slated to beginin 2Q 2022
SIOUX FALLS, S.D., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that SAB-176, its investigational therapeutic for the treatment of seasonal influenza, achieved statistically significant (p = 0.026) reductions in viral load and clinical signs and symptoms compared to placebo in a Phase 2a challenge study. In the study, SAB-176 appeared to be safe and well-tolerated. SAB-176 is a quadrivalent fully human polyclonal antibody therapeutic candidate designed for the treatment of moderate to severe Type A and B seasonal influenza viruses.
We are highly encouraged by these topline results showing that treatment with SAB-176 achieved statistical significance in reducing influenza viral load and clinical signs and symptoms in treated subjects, despite the small size of this first Phase 2 study. These data suggest that SAB-176 has the potential to be an effective treatment for this prevalent, highly-mutating virus that resurfaces annually and is a major source of hospitalizations and deaths, said Tom Luke, MD, Chief Medical Officer of SAB Biotherapeutics. These trial results support advancing SAB-176 as a potential treatment for seasonal influenza through further clinical studies, and we look forward to sharing additional data as it becomes available.
These positive efficacy data for SAB-176 represent the second clinical proof of concept achieved by our DiversitAbplatform in the past two months, said Eddie J. Sullivan, PhD, Co-Founder, President, and Chief Executive Officer of SAB Biotherapeutics. In September our investigational COVID-19 therapy SAB-185 met the pre-defined efficacy goal for advancement from Phase 2 to Phase 3 in the NIH-sponsored ACTIV-2 trial. These back-to-back clinical successes for our first two pipeline products give us confidence that the DiversitAb platform is clinically validated. They reinforce our commitment to advancing this unique platform, with its demonstrated ability to rapidly generate therapeutic candidates for highly mutating pathogen targets with ongoing resurgence and pandemic potential, including influenza and COVID-19.
About SAB-176 Challenge StudyThe Phase 2a challenge study, initiated in June 2021, was a randomized, double-blind, placebo-controlled study evaluating the safety and treatment efficacy of SAB-176 in 60 healthy adults challenged with a pandemic influenza virus strain (pH1N1). Participants were randomized to receive either SAB-176 (25 mg/kg dose) or placebo and were intranasally inoculated with pandemic H1N1 (2009/California) virus, and nasopharyngeal swabs were taken 8 days after inoculation.
The primary endpoint of the study was reduction of the nasopharyngeal viral load of subjects treated with SAB-176 (expressed as area under the curve, or AUC) compared to those receiving placebo over an 8-day timepoint as measured by qRT-PCR. SAB-176 met the primary endpoint of significantly reducing patient pH1N1 influenza viral load in the treated subjects (p = 0.026, one sided).
A secondary endpoint of the challenge study was reduction of clinical flu signs and symptoms in the subjects receiving active treatment (n=8) compared to placebo controls (n=12) for those who had signs and symptoms. SAB-176 achieved statistical significance in meeting the secondary endpoint at Day 4 (p = 0.013, one sided) in symptomatic patients. Additional analyses of secondary endpoint data are underway.
In this study SAB-176 also appeared to be safe and well tolerated. No SAB-176-related serious adverse events (SAEs) were observed, and most adverse events were mild to moderate. Based on these positive efficacy and safety results, SAB plans to further evaluate SAB-176 in advanced clinical trials.
One remarkable aspect of these results is that SABs Tc Bovine were not immunized to the specific influenza virus strain that was used in the challenge study, added Christoph Bausch, PhD, Chief Scientific Officer of SAB Biotherapeutics. Nonetheless, the statistically significant reduction in virus load and symptoms that were achieved confirm that SAB-176 demonstrated high cross reactivity to this pandemic strain. This reinforces a unique and timely feature of our DiversitAbplatformthe diversity of the human antibodies it produces gives our therapeutics the potential to be broadly neutralizing to both known and unknown viral variantsa very valuable feature when addressing rapidly mutating pathogens.
For more information on the Phase 2a clinical trial, visit clinicaltrials.gov (Identifier NCT04850898).
About SAB-176SAB-176 is a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate in development for the treatment or prevention of severe influenza. The novel, specifically-targeted therapeutic leverages the natural human biological immune response to specifically bind to Type A and Type B influenza viruses. Like vaccines, it can be modified to address annual strain changes, when needed, to maintain broader coverage as the flu virus mutates. Preclinical data suggests that SAB-176 offers broad protection against diverse influenza strains.
SABs novel DiversitAb immunotherapy platform enables the production of large amounts of targeted, highly potent human polyclonal antibodies. The platform leverages transchromosomic cattle (Tc Bovine) that have been genetically designed to generate fully human antibodies (immunoglobulin G) rather than bovine antibodies, in response to inoculation with an immunogen.
To develop and produce SAB-176, Tc Bovine were hyperimmunized with a quadrivalent antigen, including a number of influenza strains. Within a brief period of time, the Tc Bovine generated significant amounts of fully-human antibodies to combat the virus, driving titers beyond the levels known to be protective. Plasma was collected (in a similar manner as from human plasma donors), then purified to isolate the antibodies that comprise the therapeutic treatment.
About Seasonal InfluenzaInfluenza virus infection is one of the most common infectious diseases and can lead to severe illness, and death. According to the US Centers for Disease Control (CDC), on average about 8% of the US population gets sick each flu season and between 12,000 and 61,000 infected Americans die, depending on the severity of the flu season. In 2019-2020, considered a moderate flu season, 38 million people in the US became ill with the flu, 18 million saw a healthcare provider for treatment, 400,000 were hospitalized and an estimated 22,000 died. Globally, there are between 2.5 and 5 million influenza-related hospitalizations per year. The CDC recommends an annual flu shot for almost everyone over the age of six months, but each year less than half the population is vaccinated. In addition, because influenza viruses are highly mutating, the vaccines have varying levels of protection in any year, but rarely exceed 50% protection. Young children, the elderly, immune-compromised individuals, and patients with chronic health conditions are especially at risk of poor outcomes from influenza, yet there are few approved therapies for the treatment of influenza.
About SAB Biotherapeutics, Inc.SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SABs versatile DiversitAb platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs. For more information on SAB, visit: https://www.sabbiotherapeutics.com/ and follow @SABBantibody on Twitter.
Contacts:Melissa Ullerich+1 605-679-4609mullerich@sabbiotherapeutics.com
Courtney Turiano (investors)Stern IR+1 212-698-8687Courtney.Turiano@sternir.com
Forward-Looking Statements Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events. These statements are based on the current expectations of SAB and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict, will differ from assumption and are beyond the control of SAB. Forward-looking statements are subject to various risks and uncertainties, including, among others, those related to the COVID-19 pandemic; SABs ability achieve successful results for its product candidates, the availability of financing, and trends affecting SABs financial condition or results of operations. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are described under the sections entitled "Risk Factors" in the Company's proxy statement/prospectus filed with the Securities and Exchange Commission (the "SEC") on September 24, 2021. Such factors may be updated from time to time in SABs periodic filings with the SEC, which are accessible on the SECs website at http://www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The forward-looking statements speak only as of the date of this press release, and SAB expressly disclaims any obligation or undertaking to publicly update or review any forward-looking statement.
Here is the original post:
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus - BioSpace
- Viewpoint: Anti-GMO arguments seem silly after 28 years of false narratives about health harms and and genetic ... - Genetic Literacy Project - March 29th, 2024 [March 29th, 2024]
- Viewpoint: Here's how genetically engineered fruits and vegetables will soon emerge as a grocery store 'selling point ... - Genetic Literacy Project - March 29th, 2024 [March 29th, 2024]
- CRISPR Investments: What We Heard at World Agri-Tech - Seed World - March 29th, 2024 [March 29th, 2024]
- When SpaceX's Starship is ready to settle Mars, will we be? (op-ed) - Space.com - September 17th, 2023 [September 17th, 2023]
- Genome-wide promoter responses to CRISPR perturbations of ... - Nature.com - September 17th, 2023 [September 17th, 2023]
- Expanding the toolbox for RNA editing | ASU News - ASU News Now - September 17th, 2023 [September 17th, 2023]
- Electrical Engineer Named MIT Technology Review Innovator Under ... - University of California San Diego - September 17th, 2023 [September 17th, 2023]
- Can we rely on our 'moral force-field' to stop cloning going too far? - The National - September 17th, 2023 [September 17th, 2023]
- Otsuka Collaborates with ShapeTX for Development of AAV Gene ... - Pharmaceutical Technology Magazine - September 17th, 2023 [September 17th, 2023]
- Cancer discovery earns U of A grad the Breakthrough Prize - University of Alberta - September 17th, 2023 [September 17th, 2023]
- The Brave New World of synthetic humans | Gne Taylor - IAI - September 17th, 2023 [September 17th, 2023]
- Targeting Tumors with Photosynthetic Bacteria - Optics & Photonics News - September 17th, 2023 [September 17th, 2023]
- Artificial Photosynthesis Breakthrough Researchers Produce ... - SciTechDaily - September 17th, 2023 [September 17th, 2023]
- BASF patent on watermelons upheld: European Patent Office rejects ... - Bio Eco Actual - September 17th, 2023 [September 17th, 2023]
- Space Industry Is Growing Faster Than Its Workforce, Analysts Say - Slashdot - September 17th, 2023 [September 17th, 2023]
- New 'Inverse Vaccine' Shows Potential to Treat MS and Other ... - Slashdot - September 17th, 2023 [September 17th, 2023]
- Gene therapy: Donor DNA may protect babies from certain disorders - Medical News Today - May 18th, 2023 [May 18th, 2023]
- Viewpoint: Grim consequences of Greenpeace's war on ... - Genetic Literacy Project - May 18th, 2023 [May 18th, 2023]
- Predicting Diabetic Kidney Disease with the Use of a Novel Algorithm - Genetic Engineering & Biotechnology News - May 18th, 2023 [May 18th, 2023]
- Quantum biology on horizon? How futuristic physics theory could ... - Study Finds - May 18th, 2023 [May 18th, 2023]
- Scientists can collect human DNA from water, air, and basically ... - Earth.com - May 18th, 2023 [May 18th, 2023]
- The First Crispr-Edited Salad Is Here - WIRED - May 18th, 2023 [May 18th, 2023]
- Gene editing technology used to produce disease-resistant calf - Earth.com - May 18th, 2023 [May 18th, 2023]
- Neanderthals passed down their tall noses to modern humans ... - Livescience.com - May 18th, 2023 [May 18th, 2023]
- Squid Camouflage Inspires Human Invisibility: Is it Possible? - DISCOVER Magazine - May 18th, 2023 [May 18th, 2023]
- Mice Model Technologies Market Poised for 7.4% CAGR Growth, Reaching USD 3.2 Bn by 2031 | Transparency Market Research - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Google Cloud launches A.I.-powered tools to accelerate drug discovery, precision medicine - CNBC - May 18th, 2023 [May 18th, 2023]
- How Fauci, scientists with ties to Wuhan lab persuaded the ... - U.S. Right to Know - May 18th, 2023 [May 18th, 2023]
- The Daunting Task of Cutting Heavy Metals from Baby Food - Undark Magazine - May 18th, 2023 [May 18th, 2023]
- Ingestible Device Profiles and Peers into the Microbiome and ... - Genetic Engineering & Biotechnology News - May 18th, 2023 [May 18th, 2023]
- X-Men Officially Names the Best Powers Any Mutant Can Have - Screen Rant - May 18th, 2023 [May 18th, 2023]
- 10 Forgotten Marvel Comics Characters That Debuted In The '80s - Screen Rant - May 18th, 2023 [May 18th, 2023]
- 18 Human Genetic Engineering - Clemson University - April 19th, 2023 [April 19th, 2023]
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 31st, 2023 [March 31st, 2023]
- What is Genetic Engineering? Types, Process & Applications - March 31st, 2023 [March 31st, 2023]
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 31st, 2023 [March 31st, 2023]
- Welcome to the UNC Department of Genetics | Department of Genetics - February 5th, 2023 [February 5th, 2023]
- Global Genetically Modified Crops Market Is Projected To Grow At A 6% Rate Through The Forecast Period - EIN News - February 5th, 2023 [February 5th, 2023]
- Science and History of GMOs and Other Food Modification Processes - February 2nd, 2023 [February 2nd, 2023]
- Genetics | History, Biology, Timeline, & Facts | Britannica - January 31st, 2023 [January 31st, 2023]
- Human genetics | Description, Chromosomes, & Inheritance - January 31st, 2023 [January 31st, 2023]
- Genetic testing - Mayo Clinic - January 31st, 2023 [January 31st, 2023]
- Genetic Disorders: What Are They, Types, Symptoms & Causes - January 31st, 2023 [January 31st, 2023]
- Colossal Biosciences Project to Revive the Prehistoric Woolly Mammoth Raises Staggering $60 Million Series A Funding - Nature World News - January 22nd, 2023 [January 22nd, 2023]
- 2023 is going to witness a surge in technology courses top courses that will remain in vogue - Times of India - January 22nd, 2023 [January 22nd, 2023]
- M.R.S. Rao birthday: All you need to know about the Padma Shri winning Indian scientist - Free Press Journal - January 22nd, 2023 [January 22nd, 2023]
- Russian cosmism - Wikipedia - January 8th, 2023 [January 8th, 2023]
- Postgenderism - Wikipedia - January 8th, 2023 [January 8th, 2023]
- LessWrong - Wikipedia - January 8th, 2023 [January 8th, 2023]
- Eliezer Yudkowsky - Wikipedia - January 8th, 2023 [January 8th, 2023]
- Genetic Engineering Principles of Biology - December 26th, 2022 [December 26th, 2022]
- Engineering the Perfect Baby | MIT Technology Review - December 26th, 2022 [December 26th, 2022]
- Genetic Engineering Science Projects - Science Buddies - December 21st, 2022 [December 21st, 2022]
- DSI adoption at COP15 can financially help protect biodiversity in India: Experts - The Tribune India - December 21st, 2022 [December 21st, 2022]
- Tel Aviv University researchers demonstrate success of potential one-time vaccine to treat HIV/AIDS - ETHealthWorld - December 21st, 2022 [December 21st, 2022]
- Should You Buy 22nd Century Group Inc (XXII) Stock After it Has Risen 14.29% in a Week? - InvestorsObserver - October 28th, 2022 [October 28th, 2022]
- Home :: National Institute for Biotechnology and Genetic Engineering - October 11th, 2022 [October 11th, 2022]
- A recently discovered law of physics could help predict genetic mutations - October 11th, 2022 [October 11th, 2022]
- Farmers, consumers will embrace GMOs if they understand them - The Standard - October 11th, 2022 [October 11th, 2022]
- Synthetic Biology Market is Expected to Report a CAGR of ~21% from 2021 to 2029: Industry Size, Growth & Forecast at Douglas Insights - Yahoo... - October 11th, 2022 [October 11th, 2022]
- After 45 years of science-based art, Esther Klein Gallery winds down - WHYY - October 11th, 2022 [October 11th, 2022]
- Behind this Nobel prize is a very human story: theres a bit of Neanderthal in all of us - The Guardian - October 11th, 2022 [October 11th, 2022]
- The key to tastier beer might be mutant yeastwith notes of banana - Popular Science - October 11th, 2022 [October 11th, 2022]
- Why You'll Probably Never See Cotton Candy Grape Wine - Tasting Table - October 11th, 2022 [October 11th, 2022]
- Earth materials in technology The National - The National - October 11th, 2022 [October 11th, 2022]
- CULINARY THRILL SEEKING Proceed with caution. It's hotter than blazes season. - Port Arthur News - The Port Arthur News - October 11th, 2022 [October 11th, 2022]
- Give legal rights to animals, trees and rivers, say experts - The Guardian - October 11th, 2022 [October 11th, 2022]
- How yeast DNA may help protect astronauts from cosmic radiation in space - EastMojo - October 11th, 2022 [October 11th, 2022]
- Life finds a way, but should it? The ethics of genetic engineering - The Trinitonian - October 8th, 2022 [October 8th, 2022]
- To modify or not to modify? Genetic Modification and Gene Editing - A divergence by the UK - Lexology - October 8th, 2022 [October 8th, 2022]
- Gene Therapy Hits Its Stride in the Clinic - Genetic Engineering & Biotechnology News - October 8th, 2022 [October 8th, 2022]
- GWAS, MWAS and mGWAS provide insights into precision agriculture based on genotype-dependent microbial effects in foxtail millet - Nature.com - October 8th, 2022 [October 8th, 2022]
- Making Sense of the Latest Apple-iPhone News - The Motley Fool - October 8th, 2022 [October 8th, 2022]
- Gene therapy brings hope to people with sickle cell, HIV - Monitor - October 8th, 2022 [October 8th, 2022]
- GMO: Everything you need to know about lifting ban - FarmKenya Initiative - The Standard - October 8th, 2022 [October 8th, 2022]
- Century Therapeutics to Present at the SITC 37th Annual Meeting - Yahoo Finance - October 8th, 2022 [October 8th, 2022]
- Cultured meat could help solve the climate crisis. Heres what it will take to move it from the lab to the dinner table - Fortune - October 8th, 2022 [October 8th, 2022]
- Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting -... - October 8th, 2022 [October 8th, 2022]
- Explained: How scientists engineered mosquitoes that will cut the transmission of malaria - Firstpost - October 8th, 2022 [October 8th, 2022]
- Here Are the Biggest Health Industry News Items of 2022 So Far - DocWire News - October 8th, 2022 [October 8th, 2022]